Global Experts Revamp Acromegaly Treatment Guidelines for 2025
52 international experts update evidence-based recommendations for acromegaly management, incorporating new drugs and treatment algorithms.
Summary
The 15th Acromegaly Consensus Conference (September 2023) brought together 52 global experts to update therapeutic outcome recommendations for acromegaly, a rare condition of excess growth hormone typically caused by a pituitary adenoma. Since the last major guidelines in 2018, new pharmacological agents have emerged and clinical practices have evolved. The consensus reviewed somatostatin receptor ligands, the growth hormone receptor antagonist pegvisomant, and the dopamine agonist cabergoline, evaluating their effects on biochemical control, tumor mass reduction, and surgical outcomes. The resulting recommendations aim to optimize an evidence-based management algorithm for clinical practice, reflecting the latest drug approvals and real-world treatment standards.
Detailed Summary
Acromegaly is a rare but serious endocrine disorder caused predominantly by a growth hormone-secreting pituitary adenoma, leading to elevated IGF-1 levels, progressive organ damage, and reduced life expectancy if inadequately treated. Achieving biochemical and clinical control is central to improving long-term outcomes, yet management remains complex and individualized.
The 15th Acromegaly Consensus Conference, held in September 2023, convened 52 international specialists to reassess therapeutic goals and update the guidance originally published in 2018. The update was prompted by new pharmacological approvals, expanded clinical data, and evolving understanding of treatment sequencing and combination strategies.
The expert panel reviewed the current literature on three main drug classes: somatostatin receptor ligands (SRLs), the growth hormone receptor antagonist pegvisomant, and the dopamine agonist cabergoline. Each agent was evaluated for its impact on biochemical normalization, clinical symptom control, pituitary adenoma volume reduction, and its role before or after surgery. Factors influencing pharmacological selection—such as tumor characteristics, comorbidities, and patient response—were also addressed.
Key consensus recommendations emphasize an optimized, evidence-based algorithm for sequencing and combining therapies. The update incorporates newer and emerging SRL formulations and clarifies the expanded role of pegvisomant, either as monotherapy or in combination, for patients with inadequate biochemical response to first-line treatment.
Notably, this consensus is based on expert opinion and literature review rather than new prospective trial data, which is a recognized limitation in rare disease management. Additionally, many panel members disclosed relationships with pharmaceutical manufacturers of the agents discussed, warranting transparency in interpreting recommendations. Nonetheless, this update represents the most current international standard for acromegaly therapeutic decision-making.
Key Findings
- 52 global experts updated acromegaly treatment guidelines at the 2023 Consensus Conference.
- New somatostatin receptor ligands and treatment combinations have expanded options since 2018 guidelines.
- Pegvisomant's role as monotherapy or combination therapy is clarified for biochemically uncontrolled patients.
- An optimized evidence-based management algorithm is proposed to guide clinical pharmacological choices.
- Cabergoline retains a defined role in select patients alongside primary surgical and medical therapies.
Methodology
This is a consensus statement produced by 52 international acromegaly experts convened at the 15th Acromegaly Consensus Conference in September 2023. Participants performed a structured review of published literature and assessed changes in drug approvals, clinical practice, and management standards since 2018. Recommendations reflect expert consensus rather than primary data from new clinical trials.
Study Limitations
The consensus is based on expert opinion and literature review rather than new randomized controlled trial data, limiting the strength of evidence for some recommendations. Widespread conflicts of interest among panelists—many of whom have financial ties to manufacturers of the discussed drugs—introduce potential bias. As a consensus from specialist centers, recommendations may not fully reflect resource limitations in lower-income healthcare settings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.